<span style="font-size: 10pt; font-family: Arial;" data-sheets-root="1">Resiliva (Resmetirom) is a generic version of Rezdiffra which is a thyroid hormone receptor beta (THR-&beta;) agonist. By targeting THR-&beta;, it promotes lipid metabolism in the liver, reducing hepatic fat accumulation and improving lipid profiles. It is the first and only FDA-approved treatment for NASH with liver scarring, along with diet and exercise.</span>